Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Company Overview

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Key Stats

• Today's Range: $0.0146 to $0.0182
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.01 to $0.69
• Volume: 109,684 shs
• Average Volume: 1.08 million shs
• Market Capitalization: $695.52 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.75
• Consensus Rating: Hold

Viracta Therapeutics Stock Analysis - MarketRank™

Viracta Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Viracta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Viracta Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Viracta Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viracta Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viracta Therapeutics has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of Viracta Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viracta Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viracta Therapeutics has recently decreased by 23.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viracta Therapeutics does not currently pay a dividend.

Dividend Growth

Viracta Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the float of Viracta Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viracta Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viracta Therapeutics has recently decreased by 23.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for VIRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

VIRX Stock Analysis - Frequently Asked Questions

How have VIRX shares performed this year?

Viracta Therapeutics' stock was trading at $0.1609 at the beginning of 2025. Since then, VIRX stock has decreased by 89.1% and is now trading at $0.0175.
View the best growth stocks for 2025 here.

How were Viracta Therapeutics' earnings last quarter?

Viracta Therapeutics, Inc. (NASDAQ:VIRX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.09.

How do I buy shares of Viracta Therapeutics?

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viracta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/15/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIRX
• CIK: 1061027
• Web: www.viracta.com
• Phone: (858) 400-8470
• Fax: 650-266-3501
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.75
• High Stock Price Target: $3.00
• Low Stock Price Target: $0.25
• Potential Upside/Downside: +9,900.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,899.61%
• Return on Assets: -114.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.33 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 39,744,000
• Free Float: 35,495,000
• Market Cap: $695.52 thousand
• Optionable: Optionable
• Beta: 1.07